专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明专利

JP2015057428A インスリン様成長因子Ｉ受容体に対する抗体有权
标题翻译：抗胰岛素样生长因子I受体
公开(公告)号：JP2015057428A
公开(公告)日：2015-03-26
申请号：JP2014246399
申请日：2014-12-05
申请人：ファイザー・インク , Pfizer Inc , アムジェンフレモントインク. , Amgen Fremont Inc , アムジェンフレモントインク.
发明人： COHEN BRUCE D , BEEBE JEAN , MILLER PENELOPE E , MOYER JAMES D , CORVALAN JOSE R , GALLO MICHAEL
IPC分类号： A01K67/027 , C07K16/28 , A61K39/395 , A61K45/00 , A61K48/00 , A61K49/00 , A61P35/00 , A61P43/00 , C07K14/72 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/06 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N33/574 , G01N33/577 , G01N33/68
CPC分类号： C07K16/2863 , A01K2217/05 , A61K31/138 , A61K31/513 , A61K31/517 , A61K31/704 , A61K39/39541 , A61K39/39558 , A61K48/00 , A61K2039/505 , C07K14/72 , C07K16/30 , C07K16/40 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/574 , G01N33/57492 , G01N2333/65 , G01N2333/71 , A61K2300/00
摘要：【課題】インスリン様成長因子I受容体(IGF-IR)、好ましくはヒトIGF-IRに特異的に結合する抗体、およびその抗原結合部分の提供。【解決手段】キメラ抗体、二重特異性抗体、誘導体化抗体、一本鎖抗体、または融合タンパク質の部分を含む、ヒト抗IGF-IR抗体。抗IGF-IR抗体およびこのような分子をコードする核酸分子に由来する、単離された重鎖および軽鎖免疫グロブリン分子。抗IGF-IR抗体の作製、これらの抗体を含む薬学的組成物、ならびに抗体およびその組成物を診断および治療のために用いる。ヒト抗IGF-IR抗体を含む重鎖および/または軽鎖免疫グロブリン分子をコードする核酸分子を用いる、遺伝子治療。該核酸を発現する非ヒトトランスジェニック動物。【選択図】なし
摘要翻译：要解决的问题：提供与胰岛素样生长因子I受体（IGF-1R）特异性结合的抗体，优选人IGF-1R，并提供其抗原结合部分。解决方案：人抗IGF- IR抗体包括嵌合抗体，双特异性抗体，衍生抗体或单链抗体或融合蛋白的一部分。提供衍生自抗IGF-1R抗体的分离的重链和轻链免疫球蛋白分子，以及编码该分子的核酸分子。提供抗IGF-1R抗体的制备，包含该抗体的药物组合物和该抗体的用途及其组合物用于诊断和治疗。基因治疗使用编码包含人抗IGF-1R抗体的重链和/或轻链免疫球蛋白分子的核酸分子。非人转基因动物表达核酸。

2. 发明专利

JP2009297037A Antibody to insulin-like growth factor i receptor 有权
标题翻译：抗胰岛素样生长因子I受体
公开(公告)号：JP2009297037A
公开(公告)日：2009-12-24
申请号：JP2009222178
申请日：2009-09-28
申请人： Amgen Fremont Inc , Pfizer Inc , アムジェンフレモントインク. , ファイザー・インク
发明人： COHEN BRUCE D , BEEBE JEAN , MILLER PENELOPE E , MOYER JAMES D , CORVALAN JOSE R , GALLO MICHAEL
IPC分类号： A01K67/027 , C12N15/09 , A61K39/395 , A61K45/00 , A61K48/00 , A61K49/00 , A61P35/00 , A61P43/00 , C07K14/72 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/06 , C12N5/10 , C12N15/13 , C12P21/08 , G01N33/574 , G01N33/577 , G01N33/68
CPC分类号： C07K16/2863 , A01K2217/05 , A61K31/138 , A61K31/513 , A61K31/517 , A61K31/704 , A61K39/39541 , A61K39/39558 , A61K48/00 , A61K2039/505 , C07K14/72 , C07K16/30 , C07K16/40 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/574 , G01N33/57492 , G01N2333/65 , G01N2333/71 , A61K2300/00
摘要： PROBLEM TO BE SOLVED: To provide an antibody specifically binding to an insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR, and to provide an antigen-binding portion thereof. SOLUTION: A human anti-IGF-IR antibody includes a chimeric antibody, a bispecific antibody, a derivatized antibody, or a single chain antibody, or a portion of fusion proteins. An isolated heavy and light chain immunoglobulin molecule derived from an anti-IGF-IR antibody, and a nucleic acid molecule encoding the molecule are provided. Preparation of the anti-IGF-IR antibody, a pharmaceutical composition comprising the antibody, and use of the antibody, and the composition thereof for diagnosis and treatment are provided. A gene therapy uses the nucleic acid molecule encoding the heavy and/or light chain immunoglobulin molecule that comprises the human anti-IGF-IR antibody. A non-human transgenic animal expresses the nucleic acid. COPYRIGHT: (C)2010,JPO&INPIT
摘要翻译：待解决的问题：提供与胰岛素样生长因子I受体（IGF-1R）特异性结合的抗体，优选人IGF-1R，并提供其抗原结合部分。解决方案：人抗IGF-1R抗体包括嵌合抗体，双特异性抗体，衍生化抗体或单链抗体或融合蛋白的一部分。提供衍生自抗IGF-1R抗体的分离的重链和轻链免疫球蛋白分子，以及编码该分子的核酸分子。提供抗IGF-1R抗体的制备，包含该抗体的药物组合物和该抗体的用途及其组合物用于诊断和治疗。基因治疗使用编码包含人抗IGF-1R抗体的重链和/或轻链免疫球蛋白分子的核酸分子。非人转基因动物表达核酸。版权所有（C）2010，JPO＆INPIT

3. 发明专利

JP2009108055A Antibody to insulin-like growth factor i receptor 有权
标题翻译：抗胰岛素样生长因子I受体
公开(公告)号：JP2009108055A
公开(公告)日：2009-05-21
申请号：JP2008267173
申请日：2008-10-16
申请人： Amgen Fremont Inc , Pfizer Inc , アムジェンフレモントインク. , ファイザー・インク
发明人： COHEN BRUCE D , BEEBE JEAN , MILLER PENELOPE E , MOYER JAMES D , CORVALAN JOSE R , GALLO MICHAEL
IPC分类号： A01K67/027 , C07K16/28 , A61K39/395 , A61K45/00 , A61K48/00 , A61K49/00 , A61P35/00 , C07K14/72 , C07K16/46 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/06 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N33/574 , G01N33/577 , G01N33/68
CPC分类号： C07K16/2863 , A01K2217/05 , A61K31/138 , A61K31/513 , A61K31/517 , A61K31/704 , A61K39/39541 , A61K39/39558 , A61K48/00 , A61K2039/505 , C07K14/72 , C07K16/30 , C07K16/40 , C07K2317/14 , C07K2317/21 , C07K2317/56 , C07K2317/565 , C07K2317/73 , C07K2317/75 , C07K2317/76 , C07K2317/92 , G01N33/574 , G01N33/57492 , G01N2333/65 , G01N2333/71 , A61K2300/00
摘要： PROBLEM TO BE SOLVED: To provide an antibody specifically binding to insulin-like growth factor I receptor (IGF-IR), preferably human IGF-IR, and an antigen-binding site thereof. SOLUTION: The human anti-IGF-IR antibody includes chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The isolated heavy and light chain immunoglobulin molecules derived from the anti-IGF-IR antibodies and nucleic acid molecules encoding such molecules are also provided. Further, the method of making the anti-IGF-IR antibody, the pharmaceutical composition comprising these antibodies and the method of using the antibody and the composition thereof for diagnosis and treatment are provided. The gene therapy method uses nucleic acid molecules encoding the heavy and/or light chain immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The nonhuman transgenic animal expresses the nucleic acid. COPYRIGHT: (C)2009,JPO&INPIT
摘要翻译：待解决的问题：提供特异性结合胰岛素样生长因子I受体（IGF-1R），优选人IGF-1R的抗体及其抗原结合位点。解决方案：人抗IGF-1R抗体包括嵌合，双特异性，衍生的单链抗体或融合蛋白的部分。还提供了衍生自抗IGF-1R抗体的分离的重链和轻链免疫球蛋白分子以及编码这种分子的核酸分子。此外，提供了制备抗IGF-1R抗体的方法，包含这些抗体的药物组合物和使用该抗体的方法及其组合物进行诊断和治疗。基因治疗方法使用编码包含人抗IGF-1R抗体的重链和/或轻链免疫球蛋白分子的核酸分子。非人转基因动物表达核酸。版权所有（C）2009，JPO＆INPIT

4. 发明专利

AU2002231368C1 Antibodies to insulin-like growth factor I receptor 未知
公开(公告)号：AU2002231368C1
公开(公告)日：2018-08-16
申请号：AU2002231368
申请日：2001-12-20
申请人： AMGEN FREMONT INC , PFIZER
发明人： MILLER PENELOPE E , BEEBE JEAN , COHEN BRUCE D , GALLO MICHAEL , CORVALAN JOSE R , MOYER JAMES D
IPC分类号： A01K67/027 , C07K16/22 , A61K39/395 , A61K45/00 , A61K48/00 , A61K49/00 , A61P35/00 , C07K14/72 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/06 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N33/574 , G01N33/577 , G01N33/68
摘要： The present invention relates to antibodies and antigen-binding protions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such momlecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.

6. 发明专利

BG112197A АНТИТЕЛА СРЕЩУ РЕЦЕПТОРА ЗА ИНСУЛИН-ПОДОБНИЯ РАСТЕЖЕН ФАКТОР I 未知
公开(公告)号：BG112197A
公开(公告)日：2016-05-31
申请号：BG11219716
申请日：2016-01-13
申请人： PFIZER , AMGEN FREMONT INC
发明人： COHEN BRUCE , MOYER JAMES , BEEBE JEAN , CORVALAN JOSE , GALLO MICHAEL , MILLER PENELOPE
IPC分类号： A01K67/027 , C07K16/28 , A61K39/395 , A61K45/00 , A61K48/00 , A61K49/00 , A61P35/00 , C07K14/72 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/06 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N33/574 , G01N33/577 , G01N33/68
摘要： Изобретениетосеотнасядоантителатасрещурецепторазаинсулин-подобнияфактор, коитосависокоафинитетничовешкиантитела, намиратприложениев областтанамедицинатаи сеизползватзалечениеназаболяванияприхорас нарушения, катонисъкръст, слабост, остеопороза, намаленамускулнамаса, невропатияилидиабет. Стяхсеосигуряваизолираноантитялоилинеговаантиген-свързващачаст, коятосвързва IGF-IR напримати човек, запредпочитанетакова, коетое човешко. По-специалноизобретениетоосигуряваанти-IGF-IR антитяло, коетоинхибирасвързванетона IGF-I или IGF-ІІс IGF-IR исъщотакаосигуряваанти-IGF-IR антитяло, коетоактивира IGF-IR. Моноклоналнотоантитялоилинеговаантиген-свързващачастсесвързваспецифичнос човешкиярецепторзаинсулин-подобниярастеженфактор 1 (IGF-IR), къдетоспоменатотоантитяловключватрите CDR аминокиселиннисеквенцииотвариабилниядоменналекатаверига, включващаминокиселиннатасеквенцияна SEQ ID NO: 22 иливариабилниядоменнатежкатаверига, включващаминокиселиннатасеквенцияна SEQ ID NO: 24. Вединпредпочитанвариантнаизпълнениеантитялотое човешко. Изобретениетосеотнасяощедофармацевтиченсъстав, включващантитялотоилиантиген-свързващатачасти фармацевтичноприемливносител. Предвиденисаощеметодзаполучаваненаантитялото, изолиранаклетъчналиния, изолиранамолекулнануклеиновакиселина, вектор, включващмолекулатануклеиновакиселина, клетка-гостоприемники използваненаантителата. 33 претенции, 19 фигури

7. 发明专利

MY143465A ANTIBODIES TO INSULIN-LIKE GROWTH FACTOR I RECEPTOR 未知
公开(公告)号：MY143465A
公开(公告)日：2011-05-13
申请号：MYPI20015796
申请日：2001-12-20
申请人： PFIZER , AMGEN FREMONT INC
发明人： COHEN BRUCE D , BEEBE JEAN , MILLER PENELOPE E , MOYER JAMES D , CORVALAN JOSE R , GALLO MICHAEL
IPC分类号： A01K67/027 , A61K39/395 , A61K45/00 , A61K48/00 , A61K49/00 , A61P35/00 , C07K14/72 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/06 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N33/574 , G01N33/577 , G01N33/68
摘要： THE PRESENT INVENTION RELATES TO ANTIBODIES AND ANTIGEN-BINDING PORTION THEREOF THAT SPECIFICALLY BIND TO INSULIN-LIKE GROWTH FACTOR 1 RECEPTOR (IGF-IR), WHICH IS PREFERABLY HUMAN IGF-IR. THE INVENTION ALSO RELATES TO HUMAN ANTI-IGF-IR ANTIBODIES, INCLUDING CHIMERIC, BISPECIFIC, DERIVATIZED, SINGLE CHAIN ANTIBODIES OR PORTIONS OF FUSION PROTEINS. THE INVENTION ALSO RELATES TO ISOLATED HEAVY AND LIGHT CHAIN IMMUNOGLOBULIN MOLECULES DERIVED FROM ANTI-IGF-IR ANTIBODIES AND NUCLEIC ACID MOLECULES ENCODING SUCH MOLECULES. THE PRESENT INVENTION ALSO RELATES TO METHODS OF MAKING ANTI-IGF-IR ANTIBODIES, PHARMACEUTICAL COMPOSITIONS COMPRISING THESE ANTIBODIES AND METHODS OF USING THE ANTIBODIES AND COMPOSITIONS THEREOF FOR DIAGNOSIS AND TREATMENT. THE INVENTION ALSO PROVIDES GENE THERAPHY METHODS USING NUCLEIC ACID MOLECULES ENCODING THE HEAVY AND/OR LIGHT IMMUNOGLOBULIN MOLECULES THAT COMPRISE THE HUMAN ANTI-IGF-IR ANTIBODIES. THE INVENTION ALSO RELATES TO GENE THERAPHY METHOD AND TRANSGENIC ANIMALS COMPRISING NUCLEIC ACID MOLECULES OF THE PRESENT INVENTION.

8. 发明专利

CZ301712B6 Protilátka k receptoru IGF-I a farmaceutický prípravek obsahující tuto protilátku 未知
公开(公告)号：CZ301712B6
公开(公告)日：2010-06-02
申请号：CZ20032131
申请日：2001-12-20
申请人： PFIZER , AMGEN FREMONT INC
发明人： COHEN BRUCE D , BEEBE JEAN , MILLER PENELOPE E , MOYER JAMES D , CORVALAN JOSE R , GALLO MICHAEL
IPC分类号： A01K67/027 , C07K16/28 , A61K39/395 , A61K45/00 , A61K48/00 , A61K49/00 , A61P35/00 , C07K14/72 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/06 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N33/574 , G01N33/577 , G01N33/68
摘要： Humánní monoklonální protilátka nebo antigen - vazebná cást protilátky, která se specificky váže na receptor inzulínu podobného rustového faktoru I (IGF-IR), pricemž protilátka obsahuje lehký retezec, který užívá humánní gen V.kapa. A30, inhibuje vazbu IGF-I nebo IGF-II k IGF-IR a inhibuje in vivo rust nádoru. Rešení zahrnuje také odpovídající kódující molekuly nukleové kyseliny, transgenní zvírata obsahující tyto molekuly nukleové kyseliny, zpusoby prípravy anti-IGF-IR protilátky a farmaceutické prípravky, které obsahují tyto protilátky.

9. 发明专利

EE201300037A 未知
公开(公告)号：EE201300037A
公开(公告)日：2014-04-15
申请号：EEP201300037
申请日：2001-12-20
申请人： PFIZER , AMGEN FREMONT INC
发明人： COHEN BRUCE D , BEEBE JEAN , MILLER PENELOPE E , MOYER JAMES D , CORVALAN JOSE R , GALLO MICHAEL
IPC分类号： A01K67/027 , A61K39/395 , A61K45/00 , A61K48/00 , A61K49/00 , A61P35/00 , C07K14/72 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/06 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N33/574 , G01N33/577 , G01N33/68
摘要： The present invention relates to antibodies and antigen-binding protions thereof that specifically bind to insulin-like growth factor I receptor (IGF-IR), which is preferably human IGF-IR. The invention also relates to human anti-IGF-IR antibodies, including chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulin molecules derived from anti-IGF-IR antibodies and nucleic acid molecules encoding such momlecules. The present invention also relates to methods of making anti-IGF-IR antibodies, pharmaceutical compositions comprising these antibodies and methods of using the antibodies and compositions thereof for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-IGF-IR antibodies. The invention also relates to gene therapy methods and transgenic animals comprising nucleic acid molecules of the present invention.

10. 发明专利

BG111652A ANTIBODIES AGAINST THE RECEPTOR OF INSULIN-LIKE GROWTH FACTOR I 未知
公开(公告)号：BG111652A
公开(公告)日：2014-03-31
申请号：BG11165213
申请日：2013-12-13
申请人： PFIZER , AMGEN FREMONT INC
发明人： COHEN BRUCE , BEEBE JEAN , MILLER PENELOPE , MOYER JAMES , CORVALAN JOSE , GALLO MICHAEL
IPC分类号： A01K67/027 , C07K16/28 , A61K39/395 , A61K45/00 , A61K48/00 , A61K49/00 , A61P35/00 , C07K14/72 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/06 , C12N5/07 , C12N5/10 , C12N15/09 , C12N15/13 , C12P21/08 , G01N33/574 , G01N33/577 , G01N33/68
摘要： The invention relates to antibodies against the receptor of insulin-like factor, which are high affinity human antibodies. They find application in the medical field and are used for treating diseases in subjects with disorders, such as short stature, weakness, osteoporosis, reduced muscle mass, neuropathy or diabetes. They are used to provide an isolated antibody or antigen-binding portion thereof that binds IGF-IR of a primate and human, preferably one that is human antibody. In particular the invention provides an anti- IGF-IR antibody, which inhibits the binding of IGF-I or IGF-II to IGF-IR, and also provides an anti- IGF-IR that activates IGF-IR. The monoclonal antibody or antigen-binding portion thereof specifically binds the human receptor of insulin-like growth factor I (IGF-IR),wherein the said antibody comprises the three CDR amino acid sequences of the variable domain of the light chain, including the amino acid sequence of SEQ ID NO: 24. In a preferred embodiment the antibody is human antibody. The invention further relates to a pharmaceutical composition comprising the antibody or antigen-binding portion thereof and pharmaceutically acceptable carrier. A method for producing the antibody, an isolated cell line, an isolated nucleic acid molecule, a vector comprising the nucleic acid molecule, host cell and use of the antibodies, are also provided.

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式